Retinal vein occlusion

Retinal vein occlusions are blockages of the central retinal vein or one of its branches. They are more common in older people, people with high blood pressure, high cholesterol and those with a history of heart attacks, strokes, diabetes or glaucoma. Patients may notice sudden or gradual painless loss of vision or visual field defect. The two main vision-threatening complications are macular oedema and retinal ischaemia. This Clinical Management Guideline outlines the aetiology, signs and symptoms and evidence-based recommendations for diagnosing retinal vein occlusions. It highlights the need for urgent referral to their GP for medical investigation of systemic disease and baseline assessments required prior to urgent referrals to the hospital eye service.

Login to read further information on the diagnosis and management of retinal vein occlusions.

What is retinal vein occlusion?

A retinal vein occlusion is a common cause of sudden, painless reduction and vision. It occurs when a blockage, often caused by a blood clot, forms in a retinal vein. The retina is the thin membrane at the back of the eye that receives light and sends pictures of what the eye sees to the brain.  Its blood supply is drained by tiny veins.  Blockage of one of the veins draining blood out of the eye causes blood and other fluids to leak into the retina, resulting in bruising and swelling, as well as depriving the retina of oxygen. This affects the light receptor cells in the retina, which results in reduced vision

There are three types of Retinal Vein Occlusion (RVO):

  • Branch Retinal Vein Occlusion (BRVO), caused by an obstruction to one of the smaller branch veins
  • Central Retinal Vein Occlusion (CRVO), caused by an obstruction to the main vein draining blood from the retina
  • Hemi-Retinal Vein Occlusion (HRVO), caused by an obstruction to one of the two main branches of the central vein

A RVO is most likely to happen in older people, people with high blood pressure, a history of heart attack or stroke, diabetes, and in glaucoma, as well as in some rarer conditions.  How it affects the vision in the long term depends on which vessel is affected and whether this reduces the retina’s oxygen supply (‘ischaemic’ type) or does not (‘non-ischaemic’ type).  The outlook for vision is better in the non-ischaemic type.  In the ischaemic type, new blood vessels grow into the retina and the iris, which sometimes results in glaucoma.  This can be treated by closing the new vessels with the laser.

How is retinal vein occlusion managed?

The optometrist will refer the patient to an ophthalmologist (specialist eye doctor) for an urgent appointment. In addition, urgent referral to the patient’s GP may be arranged for medical management and investigation of any underlying condition. 

The main complication of RVO that affects vision is the build-up of fluid at the macula (the most sensitive part of the retina which gives the eye detailed colour vision).  Hospital treatment usually includes injections of Anti-Vascular Endothelial Growth Factor (anti-VEGF) or steroids, which has been shown to be safe and effective.

Sign in to continue

Forgotten password?
Register

Want to read the rest of this page?

If you are a member, login to view this page. If you are not a member, simply register to gain free access to the rest of this content.

Last updated

Retinal vein occlusion - 01 September 2026
The aetiology section has been updated with revised prevalence estimates and clearer classification of RVO based on anatomical location. The predisposing factors section includes additional factors that may increase the risk of developing RVO. The signs section has been expanded to include additional information on the relationship between RVO subtypes and epiretinal membrane formation. The non-pharmacological management section now outlines recommended baseline assessment and OCT features that are associated with poorer visual outcomes. The possible management section has been updated to describe interventions (including combination therapies) that may be offered for managing macular oedema, neovascularisation and associated complications.

Version 4
Date of search 11.05.26
Date of revision 04.06.26
Date of publication 01.09.26
Date for review 10.05.28
© The College of Optometrists